Macter International Limited held a corporate briefing session outlining its performance and future strategies for FY 2025-26, showcasing significant growth and expansion plans.
- Net revenue for FY 2025-26 projected at PKR 11,732M, reflecting an 18% growth year-on-year.
- Export sales increased by 147%, indicating strong international demand.
- Gross margins improved to 48%, driven by a favorable sales mix and enhanced export activities.
- The company plans to launch new products, including Pakistan’s first r-DNA biological Semaglutide, enhancing its portfolio in the diabetes management sector.
- R&D investment for FY 2026 is set at PKR 154M, emphasizing Macter's commitment to innovation and product development.
- The company maintains a diverse portfolio with over 85 active brands across major therapeutic areas.
- Macter's manufacturing capabilities include a state-of-the-art facility with a capacity of 1 million packs per day.